At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 12 enrolled
Drug / intervention
teriparatide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of PTH Combined With Weight-Bearing on Bone Density and Bone Architecture in People With Spinal Cord Injury
In Brief
A Phase 4 clinical trial evaluating teriparatide and weight-bearing for Osteoporosis and 2 related conditions. Completed, enrolled 12 participants across 1 site.
Detailed Summary
Individuals with spinal cord injury sustain significant loss of bone mass in their lower extremities (20-40% or more). This study evaluates the ability of PTH and weight-bearing, two interventions that build bone, to increase bone mass in this population.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis, Bone Loss, Spinal Cord Injury
CountriesUnited States
CollaboratorsEli Lilly and Company, Shirley Ryan AbilityLab
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 2009
Enrollment StartJun 2009
Primary CompletionMar 2012
Study CompletionDec 2012
TodayJul 2026
First PostedJan 22, 2009
Enrollment StartJun 1, 2009
Primary CompletionMar 1, 2012
Study CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 17.4 years ago
Interventions
teriparatidedrug
teriparatide 20ug daily sc for 6 months
weight-bearingother
device assisted walking